Abstract
The anti-HPV vaccine is the second vaccine for the prevention of some types of cancer, made on the basis of VLP (virus-like particle) technology. Since its appearance, it has proven effectiveness in conditions of excellent safety. This review aims at clarifying some important aspects, based on the evidence accumulated in recent years, such as the vaccines available, the number of doses, and the vaccination of particular categories – immunocompromised patients, vaccination after LEEP excisions, or vaccination in old patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
